Pfizer is preparing to sweeten its offer again for Metsera, the weight-loss drug startup at the center of a bidding war that also involves Novo Nordisk

Core Viewpoint - Pfizer is looking to enhance its bid for Metsera, a startup focused on weight-loss drugs, amidst a competitive bidding situation that includes Novo Nordisk [1] Group 1 - Pfizer is preparing to increase its offer for Metsera, indicating a strategic move to secure the acquisition [1] - Metsera is positioned as a key player in the weight-loss drug market, attracting interest from major pharmaceutical companies [1] - The bidding war highlights the growing competition in the weight-loss drug sector, particularly between Pfizer and Novo Nordisk [1]